Vor Biopharma Change In Working Capital Over Time
| VOR Stock | USD 0.87 0.02 2.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vor Biopharma Performance and Vor Biopharma Correlation. Vor |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vor Biopharma. If investors know Vor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vor Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Return On Assets (0.40) | Return On Equity (0.78) |
The market value of Vor Biopharma is measured differently than its book value, which is the value of Vor that is recorded on the company's balance sheet. Investors also form their own opinion of Vor Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Vor Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vor Biopharma's market value can be influenced by many factors that don't directly affect Vor Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vor Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vor Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vor Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Working Capital Analysis
Compare Vor Biopharma and related stocks such as Gracell Biotechnologies, Theseus Pharmaceuticals, and Monte Rosa Therapeutics Change In Working Capital Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 4.3 M | 6.3 M | (2.1 M) | 72.5 M | 76.1 M |
| ERAS | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 3.3 M | 7.7 M | 15.8 M | 813 K | 772.4 K |
| EWTX | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 1.9 M | 4.6 M | 4.1 M | (1.6 M) | (1.5 M) |
| ACET | 121.5 M | (3.8 M) | (5.5 M) | 2.9 M | 10.1 M | 29.4 M | 27.5 M | 4.3 M | (8 M) | 341 K | (13.5 M) | (6.1 M) | 2.7 M | 252 K | 239.4 K |
| CGEM | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 135 K | 6.9 M | (3.5 M) | 11.2 M | (339 K) | (322.1 K) |
| NUVL | 562 K | 562 K | 562 K | 562 K | 562 K | 562 K | 562 K | 562 K | 562 K | 562 K | 1.3 M | 1.9 M | 6.9 M | 11 M | 11.6 M |
| VTYX | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 812 K | 4 M | (5.2 M) | 5.8 M | 6.1 M |
| ACLX | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | 1.8 M | 2.7 M | 4.5 M | 225.4 M | 236.7 M |
| KNSA | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 13.9 M | 18.3 M | (17 M) | (4.3 M) | 689 K | (22.6 M) | 1.4 M | 1.4 M |
| BOLT | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 2.3 M | (2.3 M) | 20.5 M | (3.1 M) | (9.9 M) | (9.4 M) |
| DAWN | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | (357 K) | 2.7 M | 6.6 M | 9.4 M | 9.9 M |
| LYRA | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 2.1 M | (879 K) | 13.9 M | 4.6 M | (4.9 M) | (4.6 M) |
| AUTL | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | (1.2 M) | (795 K) | 5.4 M | (16.2 M) | 1.4 M | 4.1 M | 4 M | 292 K | 295.6 K |
| STTK | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | 2.2 M | 970 K | (23.5 M) | (4.5 M) | (4.1 M) | (4.3 M) |
| KYMR | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 56.7 M | 124.9 M | (61.9 M) | (37.6 M) | 2.7 M | 2.5 M |
| NRIX | (25.3 M) | (25.3 M) | (25.3 M) | (25.3 M) | (25.3 M) | (25.3 M) | (25.3 M) | (25.3 M) | 19.5 M | 36.4 M | 9.1 M | (19 M) | 20.1 M | 23.1 M | 24.3 M |
Vor Biopharma and related stocks such as Gracell Biotechnologies, Theseus Pharmaceuticals, and Monte Rosa Therapeutics Change In Working Capital description
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.My Equities
My Current Equities and Potential Positions
| Vor Biopharma | VOR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.87
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.